Problems not over for Ranbaxy as FDA issues new import alert

Months after putting forth a robust defence suggesting there were "no remnants" of past practices that led to it pay $500m towards settling an investigation by the US Department of Justice concerning data integrity and manufacturing processes at two of its Indian sites, Ranbaxy Laboratories finds itself under the regulatory spotlight yet again.